

[Type here]

Supporting Information

Synthesis and Structural Characterization of Three Unique *Helicobacter pylori* α -Cholesteryl Phosphatidyl Glucosides

Huy Q. Nguyen[†], Ryan A. Davis[†], and Jacquelyn Gervay-Hague^{†*}

jgervayhague@ucdavis.edu

[†] Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, California 95616, United States

Table of Contents

General information	S6
Synthesis of 1-(tetradecanoyl)-3- <i>O</i> -benzyl- <i>sn</i> -glycerol (8) and 1,2-(tetradecanoyl)-3- <i>O</i> -benzyl <i>sn</i> -glycerol (9)	S7-8
Synthesis of 1-(tetradecanoyl)-2-(9 <i>Z</i> -octadecanoyl)-3- <i>O</i> -benzyl <i>sn</i> -glycerol (10)	S8-9
Synthesis of 1-(tetradecanoyl)-2-(9-cyclopropyl-nonadecanoyl)-3- <i>O</i> -benzyl <i>sn</i> -glycerol (11)	S9
General protocol for debenzylation	S10
Synthesis of 1,2-(tetradecanoyl)- <i>sn</i> -glycerol (5) ¹	S10
Synthesis of 1-(tetradecanoyl)-2-(9-cyclopropyl-nonadecanoyl)- <i>sn</i> -glycerol (12)	S10-11
General protocol for the synthesis of diacylglycerol phosphoramidite (13-15)	S11
Synthesis of 2-cyanoethyl- <i>N,N</i> -diisopropylamine-(1,2-tetradecanoyl)- <i>sn</i> -glycero)-3-phosphoramidite (13)	S12
Synthesis of 2-cyanoethyl- <i>N,N</i> -diisopropylamine-(1-hexadecanoyl-2-(9 <i>Z</i> -octadecanoyl)- <i>sn</i> -glycero)-3-phosphoramidite (14)	S13-14
Synthesis of 2-cyanoethyl- <i>N,N</i> -diisopropylamine-(1-hexadecanoyl-2-(9-cyclopropyl-nonadecanoyl)- <i>sn</i> -glycero)-3-phosphoramidite (15)	S14-15
Synthesis of cholesteryl 2,3,4,6-tetra- <i>O</i> -trimethylsilyl- α -D-glucopyranoside (4)	S16-17
Synthesis of cholesteryl 2,3,4-tri- <i>O</i> -trimethylsilyl- α -D-glucopyranoside (16)	S17-18
Synthesis of cholesteryl 6- <i>O</i> -(1,2-tetradecanoyl- <i>sn</i> -glycero-3-phosphocynoethyl)- α -D-glucopyranoside (17)	S18-19
Synthesis of cholesteryl 6- <i>O</i> -(1-hexadecanoyl-2-(9 <i>Z</i> -octadecanoyl)- <i>sn</i> -glycero-3-	S19-21

[Type here]

phosphocyanoethyl)- α -D-glucopyranoside (18)	
Synthesis of cholesteryl 6- <i>O</i> -(1-tetradecanoyl-2-(9-cyclopropyl-nonadecanoyl)- <i>sn</i> -glycero-3-phosphocyanoethyl)- α -D-glucopyranoside (19)	S21-22
General protocol for the deprotection of 17-19	S23
Synthesis of cholesteryl 6- <i>O</i> -(1,2-hexadecanoyl- <i>sn</i> -glycero-3-phosphate)- α -D-glucopyranoside (3a)	S23-24
Synthesis of cholesteryl 6- <i>O</i> -(1-hexadecanoyl-2-(9 <i>Z</i> -octadecanoyl)- <i>sn</i> -glycero-3-phosphate)- α -D-glucopyranoside (3b)	S24-25
Synthesis of cholesteryl 6- <i>O</i> -(1-tetradecanoyl-2-(9-cyclopropyl-nonadecanoyl)- <i>sn</i> -glycero-3-phosphate)- α -D-glucopyranoside (3c)	S25-26
References	S26
¹ H NMR spectrum of compound (4) (C ₆ D ₆ , 600 MHz)	S27
¹³ C NMR spectrum of compound (4) (C ₆ D ₆ , 150 MHz)	S28
DEPT135 spectrum of compound (4) (C ₆ D ₆ , 150 MHz)	S29
¹ H- ¹ H COSY spectrum of compound (4) (C ₆ D ₆ , 600 MHz)	S30
¹ H- ¹³ C HSQC spectrum of compound (4) (C ₆ D ₆ , 600 MHz)	S31
¹ H- ¹³ C HMBC spectrum of compound (4) (C ₆ D ₆ , 600 MHz)	S32
¹ H NMR spectrum of compound (16) (C ₆ D ₆ , 600 MHz)	S33
¹³ C NMR spectrum of compound (16) (C ₆ D ₆ , 150 MHz)	S34
DEPT135 spectrum of compound (16) (C ₆ D ₆ , 150 MHz)	S35
¹ H- ¹ H COSY spectrum of compound (16) (C ₆ D ₆ , 600 MHz)	S36
¹ H- ¹³ C HSQC spectrum of compound (16) (C ₆ D ₆ , 600 MHz)	S37-S38
¹ H NMR spectrum of compound (8) (C ₆ D ₆ , 600 MHz)	S39
¹³ C NMR spectrum of compound (8) (C ₆ D ₆ , 150 MHz)	S40
DEPT135 spectrum of compound (8) (C ₆ D ₆ , 150 MHz)	S41
¹ H- ¹ H COSY spectrum of compound (8) (C ₆ D ₆ , 600 MHz)	S42
¹ H- ¹³ C HSQC spectrum of compound (8) (C ₆ D ₆ , 600 MHz)	S43
¹ H- ¹³ C HMBC spectrum of compound (8) (C ₆ D ₆ , 600 MHz)	S44
¹ H NMR spectrum of compound (10) (CDCl ₃ , 600 MHz)	S45
¹³ C NMR spectrum of compound (10) (CDCl ₃ , 150 MHz)	S46
DEPT135 spectrum of compound (10) (CDCl ₃ , 150 MHz)	S47

[Type here]

^1H - ^1H COSY spectrum of compound (10) (CDCl_3 , 600 MHz)	S48
^1H - ^{13}C HSQC spectrum of compound (10) (CDCl_3 , 600 MHz)	S49
^1H - ^{13}C HMBC spectrum of compound (10) (CDCl_3 , 600 MHz)	S50
^1H NMR spectrum of compound (11) (CDCl_3 , 800 MHz)	S51
^{13}C NMR spectrum of compound (11) (CDCl_3 , 200 MHz)	S52
DEPT135 spectrum of compound (11) (CDCl_3 , 200 MHz)	S53
^1H - ^1H COSY spectrum of compound (11) (CDCl_3 , 800 MHz)	S54
^1H - ^{13}C HSQC NMR spectrum of compound (11) (CDCl_3 , 800 MHz)	S55
^1H - ^{13}C HMBC spectrum of compound (11) (CDCl_3 , 800 MHz)	S56
^1H NMR spectrum of compound (12) (CDCl_3 , 800 MHz)	S57
^{13}C NMR spectrum of compound (12) (CDCl_3 , 200 MHz)	S58
DEPT135 spectrum of compound (12) (CDCl_3 , 200 MHz)	S59
^1H - ^1H COSY spectrum of compound (12) (CDCl_3 , 800 MHz)	S60
^1H - ^{13}C HSQC NMR spectrum of compound (12) (CDCl_3 , 800 MHz)	S61
^1H - ^{13}C HMBC spectrum of compound (12) (CDCl_3 , 800 MHz)	S62
^1H NMR spectrum of compound (13) (C_6D_6 , 800 MHz)	S63
^{13}C NMR spectrum of compound (13) (C_6D_6 , 200 MHz)	S64
DEPT135 spectrum of compound (13) (C_6D_6 , 200 MHz)	S65
^1H - ^1H COSY spectrum of compound (13) (C_6D_6 , 800 MHz)	S66
^1H - ^{13}C HSQC spectrum of compound (13) (C_6D_6 , 800 MHz)	S67
^1H - ^{13}C HMBC spectrum of compound (13) (C_6D_6 , 800 MHz)	S68
^{31}P NMR spectrum of compound (13) (C_6D_6 , 200 MHz)	S69
^1H NMR spectrum of compound (14) (CDCl_3 , 800 MHz)	S70
^{13}C NMR spectrum of compound (14) (CDCl_3 , 200 MHz)	S71
DEPT135 spectrum of compound (14) (CDCl_3 , 200 MHz)	S72
^1H - ^1H COSY spectrum of compound (14) (CDCl_3 , 800 MHz)	S73
^{31}P NMR spectrum of compound (14) (CDCl_3 , 200 MHz)	S74
^1H NMR spectrum of compound (15) (CDCl_3 , 600 MHz)	S75
^{13}C NMR spectrum of compound (15) (CDCl_3 , 150 MHz)	S76
DEPT135 spectrum of compound (15) (CDCl_3 , 150 MHz)	S77
^1H - ^1H COSY spectrum of compound (15) (CDCl_3 , 600 MHz)	S78

[Type here]

¹ H- ¹³ C HSQC spectrum of compound (15) (CDCl ₃ , 600 MHz)	S79
¹ H- ¹³ C HMBC spectrum of compound (15) (CDCl ₃ , 600 MHz)	S80
³¹ P NMR spectrum of compound (15) (CDCl ₃ , 200 MHz)	S81
¹ H NMR spectrum of compound (17) (CDCl ₃ :MeOD 5:1, 600 MHz)	S82
¹³ C NMR spectrum of compound (17) (CDCl ₃ :MeOD 5:1, 150 MHz)	S83
DEPT135 spectrum of compound (17) (CDCl ₃ :MeOD 5:1, 150 MHz)	S84-85
¹ H- ¹ H COSY spectrum of compound (17) (CDCl ₃ :MeOD 5:1, 600 MHz)	S86
¹ H- ¹³ C HSQC spectrum of compound (17) (CDCl ₃ :MeOD 5:1, 600 MHz)	S87
¹ H- ¹³ C HMBC spectrum of compound (17) (CDCl ₃ :MeOD 5:1, 600 MHz)	S88
³¹ P NMR spectrum of compound (17) (CDCl ₃ :MeOD 5:1, 200 MHz)	S89
HRMS (ESI-Ion Trap) spectrum of compound (17)	S90
¹ H NMR spectrum of compound (18) (CDCl ₃ :MeOD 5:1, 600 MHz)	S91
DEPT135 spectrum of compound (18) (CDCl ₃ :MeOD 5:1, 150 MHz)	S92
¹ H- ¹ H COSY spectrum of compound (18) (CDCl ₃ :MeOD 5:1, 600 MHz)	S93
¹ H NMR spectrum of compound (18) (C ₅ D ₅ N:MeOD, 600 MHz)	S94
¹³ C NMR spectrum of compound (18) (C ₅ D ₅ N:MeOD, 150 MHz)	S95
DEPT135 spectrum of compound (18) (C ₅ D ₅ N:MeOD, 150 MHz)	S96
¹ H- ¹ H COSY spectrum of compound (18) (C ₅ D ₅ N:MeOD, 600 MHz)	S97
¹ H- ¹³ C HSQC spectrum of compound (18) (C ₅ D ₅ N:MeOD, 600 MHz)	S98
¹ H- ¹³ C HMBC spectrum of compound (18) (C ₅ D ₅ N:MeOD, 600 MHz)	S99
³¹ P NMR spectrum of compound (18) (C ₅ D ₅ N:MeOD, 200 MHz)	S100
¹ H NMR spectrum of compound (19) (CDCl ₃ :MeOD 1:1, 800 MHz)	S101
¹³ C NMR spectrum of compound (19) (CDCl ₃ :MeOD 1:1, 800 MHz)	S102
DEPT135 spectrum of compound (19) (CDCl ₃ :MeOD 1:1, 800 MHz)	S103
¹ H- ¹ H COSY spectrum of compound (19) (CDCl ₃ :MeOD 1:1, 800 MHz)	S104
¹ H- ¹³ C HSQC spectrum of compound (19) (CDCl ₃ :MeOD 1:1, 800 MHz)	S105
¹ H- ¹³ C HMBC spectrum of compound (19) (CDCl ₃ :MeOD 1:1, 800 MHz)	S106
³¹ P NMR spectrum of compound (19) (CDCl ₃ :MeOD 1:1, 800 MHz)	S107
HRMS (ESI-Ion Trap) spectrum of compound (19)	S108-109
¹ H NMR spectrum of compound (3a) (CDCl ₃ :MeOD:TEA 4:1.5:0.5, 600 MHz)	S110

[Type here]


¹³ C NMR spectrum of compound (3a) (CDCl ₃ :MeOD:TEA 4:1.5:0.5, 150 MHz)	S111
DEPT135 spectrum of compound (3a) (CDCl ₃ :MeOD:TEA 4:1.5:0.5, 150 MHz)	S112
¹ H- ¹ H COSY spectrum of compound (3a) (CDCl ₃ :MeOD:TEA 4:1.5:0.5, 600 MHz)	S113
¹ H- ¹³ C HSQC spectrum of compound (3a) (CDCl ₃ :MeOD:TEA 4:1.5:0.5, 600 MHz)	S114
¹ H- ¹³ C HMBC spectrum of compound (3a) (CDCl ₃ :MeOD:TEA 4:1.5:0.5, 600 MHz)	S115
³¹ P NMR spectrum of compound (3a) (CDCl ₃ :MeOD:TEA 4:1.5:0.5, 200 MHz)	S116
HRMS (ESI-Ion Trap) spectrum of compound (3a)	S117
¹ H NMR spectrum of compound (3b) (CDCl ₃ :DBU:CD ₃ COOD, 800 MHz)	S118
¹³ C NMR spectrum of compound (3b) (CDCl ₃ :DBU:CD ₃ COOD, 200 MHz)	S119
DEPT135 spectrum of compound (3b) (CDCl ₃ :DBU:CD ₃ COOD, 200 MHz)	S120
¹ H- ¹ H COSY spectrum of compound (3b) (CDCl ₃ :DBU:CD ₃ COOD, 800 MHz)	S121
¹ H- ¹³ C HSQC spectrum of compound (3b) (CDCl ₃ :DBU:CD ₃ COOD, 800 MHz)	S122
³¹ P NMR spectrum of compound (3b) (CDCl ₃ :DBU:CD ₃ COOD, 200 MHz)	S123
HRMS (ESI-Ion Trap) spectrum of compound (3b)	S124-125
¹ H NMR spectrum of 1,8-Diazabicyclo[5.4.0]undec-7-ene (CDCl ₃ , 600 MHz)	S126
¹³ C NMR spectrum of 1,8-Diazabicyclo[5.4.0]undec-7-ene (CDCl ₃ , 600 MHz)	S127
¹ H NMR spectrum of compound (3c) (CDCl ₃ :MeOD 1:1, 800 MHz)	S128
¹³ C NMR spectrum of compound (3c) (CDCl ₃ :MeOD 1:1, 200 MHz)	S129
DEPT135 spectrum of compound (3c) (CDCl ₃ :MeOD 1:1, 200 MHz)	S130
¹ H- ¹ H COSY spectrum of compound (3c) (CDCl ₃ :MeOD 1:1, 800 MHz)	S131
¹ H- ¹³ C HSQC spectrum of compound (3c) (CDCl ₃ :MeOD 1:1, 800 MHz)	S132
³¹ P NMR spectrum of compound (3c) (CDCl ₃ :MeOD 1:1, 200 MHz)	S133
HRMS (ESI-Ion Trap) spectrum of compound (3c)	S134-135

General Experimental

[Type here]

All reactions were conducted under a dry argon atmosphere. Solvents including tetrahydrofuran (THF) 99.9%, chloroform (CHCl₃) 99.9%, pyridine (pyr) 99.0%, acetone 99.8%, dichloromethane (CH₂Cl₂) 99.9%, and methanol 99.8% were purchased as anhydrous in a sure seal bottle under argon atmosphere. To insure that solvents were extra dry, they were subjected to activated molecular sieves. Trimethylsilyl iodide (TMSI) was stored at -15 °C in a sealed jar of drierite. Cholesterol (95%) and tetrabutylammonium iodide (TBAI) were stored at 80 °C under vacuum for at least 48 h prior to use. All other chemical reagents were commercial grade and used without further purification. Glass-backed TLC plates (Silica Gel 60 with a 254 nm fluorescent indicator) were used without further manipulation and stored over desiccant. Developed TLC plates were visualized with ammonium molybdate/cerium (IV) sulfate stain and heat provided by a hotplate. Silica gel flash column chromatography was performed using flash silica gel (32-63 μm) and employed a solvent polarity correlated with TLC mobility. NMR spectra were obtained using a 500 and 600 spectrometers and are reported in parts per million (δ) relative to chloroform (¹H NMR δ = 7.26, ¹³C NMR δ = 77.16) or methanol (¹H NMR δ = 3.31, ¹³C NMR δ = 49.0). ³¹P NMR was taken on a 300 MHz (120 MHz) and an AV-500 (200 MHz). Coupling constants (*J*), of proximal nuclei were averaged to match. High resonance mass spectrometry samples were analyzed either by electrospray ionization mass spectrometry in positive mode using flow-injection analysis. Optical rotations were measured at 598 nm using a commercial polarimeter, in a 100 mm cell or 10 mm cell.

[Type here]




1-(Tetradecanoyl)-3-*O*-benzyl-*sn*-glycerol (**8**) and 1,2-(tetradecanoyl)-3-*O*-benzyl *sn*-

glycerol (9): Diol **7**¹ (2.88 g, 15.8 mmol) was azeotropically dried with benzene (3 x 4 mL) and placed under high vacuum overnight. Myristic acid (4.33 g, 18.9 mmol) and DMAP (0.20 g, 1.60 mmol) was added to **7** and then dissolved with dry CH₂Cl₂ (12 mL) under argon. A solution of DCC (4.89 g, 23.7 mmol) in dry CH₂Cl₂ (8 mL) was transferred to the reaction vessel containing **7** via cannula over 20 min at 0 °C. The reaction was allowed warm to rt and stirred overnight. The white suspension was diluted with CH₂Cl₂ (~20 mL) and filtered over a pad of celite. After concentrating the filtrate, the crude oil was purified by gradient flash column chromatography (5 →30% EtOAc:hexanes) to afford **8**¹ (4.37 g, 70% yield) and **9**¹ (2.18 g, 23% yield). Characterization for compound **8**: $[\alpha]_{\text{D}}^{25} +2.67$ (*c* 0.006, CHCl₃); $R_f = 0.35$ (4:1 hexanes:EtOAc); ¹H NMR (600 MHz, C₆D₆): δ 7.21 - 7.09 (m, Ph, 5H), 4.29 (s, O-CH₂, 2H), 4.18 (d, *J* = 5.5 Hz, *sn*-1-CH₂, 2H), 3.97-3.95 (m, *sn*-2-CH, 1H), 3.34 (dd, *J* = 5.8, 4.8 Hz, *sn*-3-

[Type here]


CH₂, 2H), 3.19 (d, $J = 4.8$ Hz, *sn*-2-OH, 1H), 2.15 (t, $J = 7.7$ Hz, CO-CH₂, 2H), 1.56 – 1.54 (m, 2H), 1.30 – 1.19 (m, 20H), 0.90 (t, $J = 7.3$ Hz, CH₃, 3H); ¹³C NMR (150 MHz, C₆D₆): δ 173.4 (C=O), 138.6, 128.6, 127.9, 127.8, 73.5, 71.6, 69.1, 65.8, 34.3, 32.4, 30.2, 30.2, 30.1, 30.0, 29.6, 29.8, 29.5, 25.3, 23.1, 14.4; HRMS (ESI-Ion Trap) m/z : [M+Na]⁺ calcd for C₂₄H₄₀O₄Na, 415.2819; found . Characterization for compound **9**¹: $R_f = 0.74$ (4:1 hexanes:EtOAc).



1-(Tetradecanoyl)-2-(9Z-octadecanoyl)-3-O-benzyl *sn*-glycerol (10): A solution of DCC (2.62 g, 12.7 mmol) was added dropwise via a cannula to a solution of compound **8** (3.32 g, 8.46 mmol), DMAP (0.10 g, 0.85 mmol), and oleic acid (2.87 g, 10.1 mmol) over 25 min at room temperature. The suspension was stirred for 20 h at rt and then filtered through celite. The celite was washed with CH₂Cl₂ and the filtrate was concentrated to a crude product that was purified by gradient flash column chromatography (5→10% EtOAc:hexanes) to afford **10** (3.72 g, 67% yield) as a clear oil: $[\alpha]_D^{25} +1.56$ (c 0.012, CHCl₃); $R_f = 0.70$ (4:1 hexanes/EtOAc 9:1); ¹H NMR (600 MHz, CDCl₃): δ 7.24–7.17 (m, Ph, 5H), 5.27–5.25 (m, HC=CH, 2H), 5.17 – 5.15 (m, *sn*-2-CH, 1H), 4.47 (d, $J = 11.9$ Hz, O-CH₂, 1H), 4.43 (d, $J = 11.9$ Hz, O-CH₂, 1H), 4.27 (dd, $J = 11.9, 3.8$ Hz, *sn*-1-CHa, 1H), 4.11 (dd, $J = 11.8, 6.4$ Hz, *sn*-1-CHb, 1H), 3.50 (dd, $J = 5.2, 2.1$ Hz, *sn*-3-CH₂, 2H), 2.23 (t, $J = 7.5$ Hz, CO-CH₂, 2H), 2.19 (t, $J = 7.5$ Hz, CO-CH₂, 2H), 1.93 (dt, $J = 13.4, 6.6$ Hz, 4H), 1.52 (m, 4H), 1.25 – 1.17 (m, 40H), 0.80 (t, $J = 7.1$ Hz, 2xCH₃, 6H); ¹³C NMR (150 MHz, CDCl₃): δ 173.3, 173.0, 137.8, 130.0, 129.7, 128.4, 127.8, 127.7, 73.3, 70.1, 68.3, 62.7, 34.3, 34.2, 32.0, 32.0, 29.8, 29.8, 29.8, 29.7, 29.7, 29.6, 29.5, 29.4, 29.4, 29.3, 29.3, 29.2, 29.2,

[Type here]


29.1, 27.3, 27.2, 25.0, 24.9, 22.8, 22.7, 14.2; HRMS (ESI-Ion Trap) m/z : $[M+NH_4]^+$ calcd for $C_{42}H_{76}NO_5^+$, 674.5718; found 674.5730.




1-(Tetradecanoyl)-2-(9-cyclopropyl-nonadecanoyl)-3-O-benzyl *sn*-glycerol (11): Compound **10** (3.70 g, 6.00 mmol), Zn/Cu (1.67 g, 13.0 mmol), and CH_2I_2 (1.81 mL, 23.0 mmol) were suspended with Et_2O (30 mL). The suspension was then refluxed (40 °C) for 15 h. Water (30 mL) was added and then the suspension was filtered through a pad of celite. The filtrate was extracted with Et_2O and then the organic layer was washed with aqueous NH_4Cl and sat. $NaHCO_3$. After drying over $MgSO_4$, the crude was concentrated and purified by gradient flash column chromatography (0 →8% $EtOAc$:hexanes) to afford **11** as a clear oil (2.35 g, 62% yield): $[\alpha]_D^{25} +4.43$ (c 0.010, $CHCl_3$); $R_f = 0.38$ (9:1 hexanes: $EtOAc$); 1H NMR (800 MHz, $CDCl_3$): δ 7.30 – 7.21 (m, Ph, 5H), 5.21 – 5.19 (m, *sn*-2-CH, 1H), 4.51 (d, $J = 12.2$ Hz, O- CH_{2a} , 1H), 4.47 (d, $J = 12.2$ Hz, O- CH_{2b} , 1H), 4.31 (dd, $J = 11.8, 3.8$ Hz, *sn*-1-CH_a, 1H), 4.15 (dd, $J = 11.8, 6.4$ Hz, *sn*-1-CH_b, 1H), 3.54 (dd, $J = 5.1, 2.1$ Hz, *sn*-3- CH_2 , 2H), 2.27 (t, $J = 7.5$ Hz, CO- CH_2 , 2H), 2.23 (t, $J = 7.5$ Hz, CO- CH_2 , 2H), 1.58 – 1.52 (m, 4H), 1.33 – 1.08 (m, 48H), 0.83 (t, $J = 6.7$ Hz, CH_3 , 6H), 0.63 – 0.56 (m, cyclopropyl 2xCH, 2H), 0.52 (ddd, $J = 9.7, 4.16, 4.10$ Hz, cyclopropyl CH_{2a} , 1H), -0.38 (app. q, $J = 9.7, 5.3, 4.16$ Hz, cyclopropyl CH_{2b} , 1H); ^{13}C NMR (200 MHz, $CDCl_3$): δ 173.3, 173.0, 137.8, 128.4, 127.8, 127.7, 73.3 (O- CH_2), 70.0 (*sn*-2-CH), 68.3 (*sn*-3- CH_2), 62.7 (*sn*-1- CH_2), 34.4, 34.1, 32.0, 30.3, 30.2, 29.8, 29.8, 29.7, 29.7, 29.6, 29.5, 29.4, 29.4, 29.4, 29.3, 29.2, 29.1, 28.8, 28.7, 25.0, 24.9, 22.8, 22.7, 15.8, 15.7, 14.2, 11.0 (cyclopropyl CH_2); HRMS (ESI-Ion Trap) m/z : $[M+NH_4]^+$ calcd for $C_{43}H_{78}NO_5^+$, 688.5875; found 688.5874.

[Type here]

General protocol for debenzylation: Diacyl-*O*-benzyl glycerol (**9** and **11**) and Pd(OH)₂/C (10% wt. of diacylglycerol) were suspended with CH₂Cl₂:MeOH (~10 mL). Then H₂ (g) 1 atm was bubbled into the suspension for 30 min. After stirring at rt for 2 h, the suspension was filtered through a pad of celite. The filtrate was then concentrated and purified by gradient flash column chromatography (5 →20% EtOAc:hexanes) to afford a clear oil.



1,2-(Tetradecanoyl)-*sn*-glycerol (5**)¹:** Compound **9** (1.00 g, 1.65 mmol) was debenzylated and purified to afford **5** (0.85 g, quant. yield) as a clear oil: R_f = 0.28 (4:1 hexanes:EtOAc); ¹H NMR (800 MHz, CDCl₃): δ 5.08 (app. quin, *J* = 5.1, 5.1, 5.1, 5.0 Hz, *sn*-2-CH, 1H), 4.32 (dd, *J* = 11.9, 4.5 Hz, *sn*-1-CH_a, 1H), 4.24 (dd, *J* = 11.9, 5.7 Hz, *sn*-1-CH_b, 1H), 3.73 (app. d, *J* = 3.1 Hz, *sn*-3-CH₂, 2H), 2.34 (t, *J* = 7.6 Hz, CO-CH₂, 2H), 2.32 (t, *J* = 7.6 Hz, CO-CH₂, 2H), 2.04 (br. s, *sn*-3-OH, 1H), 1.63 – 1.58 (m, 4H), 1.30 – 1.25 (m, 40H), 0.88 (t, *J* = 7.1 Hz, CH₃, 3H); ¹³C NMR (200 MHz, CDCl₃): δ 174.0, 173.6, 72.2 (*sn*-2-CH), 62.1 (*sn*-1-CH₂), 61.7 (*sn*-3-CH₂), 34.4, 34.3, 32.1, 29.8, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 25.1, 25.0, 22.8, 14.3.




1-(Tetradecanoyl)-2-(9-cyclopropyl-nonadecanoyl)-*sn*-glycerol (12**):** Compound **11** (0.40 g, 0.60 mmol) was debenzylated and purified to afford **12** (0.32 g, 90% yield) as a clear oil: [α]_D²⁵ -

[Type here]

1.67 (*c* 0.002, CHCl₃); R_f = 0.36 (4:1 hexanes:EtOAc); ¹H NMR (600 MHz, C₆D₆): δ 5.19 – 5.16 (m, *sn*-2-CH, 1H), 4.36 (dd, *J* = 12.0, 3.8 Hz, *sn*-1-CH_a, 1H), 4.17 (dd, *J* = 12.0, 6.2 Hz, *sn*-1-CH_b, 1H), 3.51 (d, *J* = 3.7 Hz, *sn*-3-CH₂, 2H), 2.19 (t, *J* = 7.9 Hz, CO-CH₂, 2H), 2.15 (t, *J* = 7.9 Hz, CO-CH₂, 2H), 1.60-1.55 (m, 4H), 1.47 – 1.40 (m, 5H), 1.37 – 1.18 (m, 40H), 0.91 (t, *J* = 6.0 Hz, CH₃, 6H), 0.71 – 0.68 (m, cyclopropyl CH, 2H), 0.67 – 0.65 (m, cyclopropyl CH_{2a}, 1H), -0.24 (app. q, *J* = 4.9, 4.8, 4.2 Hz, cyclopropyl CH_{2b}); ¹³C NMR (150 MHz, C₆D₆): δ 173.2, 173.1, 72.6 (*sn*-2-CH), 62.7 (*sn*-1-CH₂), 61.5 (*sn*-3-CH₂), 34.5, 34.2, 32.4, 30.8, 30.7, 30.2, 30.2, 30.2, 30.1, 30.0, 30.0, 29.9, 29.8, 29.7, 29.5, 29.3, 29.2, 25.3, 25.2, 23.2, 16.3 (cyclopropyl CH), 16.2 (cyclopropyl CH), 14.4, 11.5 (cyclopropyl CH₂); HRMS (ESI-Ion Trap) *m/z*: [M+H]⁺ calcd for C₃₆H₆₉O₅⁺, 581.5140; found 581.5130.

General protocol for the synthesis of diacylglycerol phosphoramidite (13-15): The diacylglycerol (**5-6,12**) was azeotropically dried with dry benzene (3 x 2 mL) and placed under high vacuum for 4 h. The dry oil/gel was diluted in dry CH₂Cl₂ (0.1 M) and then bisdiisopropylamine cyanoethyl phosphoramidite (1.2–2.0 eq) was added to the reaction solution followed by the addition of tetrazole (0.45 M in CH₃CN, 1.0-2.0 eq). The reaction was monitored by TLC and allowed to stir at rt for 1 h before diluting with degassed CH₂Cl₂ (~10 mL). The organic phase was washed with degassed sat. NaHCO₃ and dried over MgSO₄. Once filtered and concentrated, the crude product was purified by gradient flash column chromatography (pre-treated with 3% TEA, 5 →20 % EtOAc:hexanes) to afford a mixture of diastereomers as a colorless oil: R_f = 0.50 (4:1 hexanes:EtOAc).


[Type here]



2-Cyanoethyl-*N,N*-diisopropylamine-(1,2-hexadecanoyl)-*sn*-glycero)-3-phosphoramidite

(13): Diacylglycerol **5** (0.15 g, 0.30 mmol) was dissolved with dry CH₂Cl₂ (1.00 mL). Bisdiisopropylamine cyanoethyl phosphoramidite (0.19 mL, 0.59 mmol) was added followed by the addition of tetrazole (0.45 M in CH₃CN, 1.32 mL, 0.59 mmol). After 1 h at rt, the reaction was quenched and worked up as described in the general protocol. The crude mixture was purified by flash column chromatography to afford a mixture of diastereomers **13** (0.16 g, 77% yield) as a clear oil: R_f = 0.60 (4:1 hexanes:EtOAc); ¹H NMR (800 MHz, C₆D₆): δ 5.41 – 5.40 (m, *sn*-2-CH, 1H), 4.52 (dd, *J* = 11.9, 3.6 Hz, *sn*-1-CH_a, 0.5H), 4.44 (dd, *J* = 11.9, 3.6 Hz, *sn*-1-CH_a, 0.5H), 4.27 – 4.23 (m, *sn*-1-CH_b, 1H), 3.84 – 3.80 (m, *sn*-3-CH₂, 1H), 3.76 -3.68 (m, *sn*-3-CH₂, 1H), 3.52 – 3.49 (m, 2 x N-CH, 2H), 3.40 – 3.26 (m, PO-CH₂, 2H), 2.25 – 2.22 (m, CO-CH₂, 2H), 2.19 – 2.17 (m, CO-CH₂, 2H), 1.84 – 1.79 (m, NC-CH₂, 2H), 1.62 – 1.57 (m, 4H), 1.32 – 1.21 (m, 40H), 1.12 – 1.10 (m, 4 x CHCH₃, 12H), 0.91 (t, *J* = 7.1 Hz, 2 x CH₃, 6H); ¹³C NMR (200 MHz, C₆D₆): δ 172.8, 172.6 (d, *J* = 3.6 Hz, *sn*-2-CO), 117.5 (d, *J* = 3.4 Hz, CN), 71.2 (app. t, *J* = 7.8, 7.8 Hz, *sn*-2-CH), 62.7 (d, *J* = 1.8 Hz, *sn*-1-CH₂), 62.2 (d, *J* = 15.9 Hz, *sn*-3-CH₂), 62.1 (d, *J* = 16.2 Hz, *sn*-3-CH₂), 58.9 (d, *J* = 18.4 Hz, PO-CH₂), 58.8 (d, *J* = 18.8 Hz, PO-CH₂), 43.5 (d, *J* = 4.7 Hz, N-CH), 43.4 (d, *J* = 4.7 Hz, N-CH), 34.5, 34.3, 32.4, 30.2, 30.2, 30.2, 30.1, 30.0, 29.9, 29.8, 29.7, 29.5, 25.3, 25.2, 24.7, 24.6, 23.1, 20.1 (d, *J* = 6.5 Hz, NC-CH₂), 14.4; ³¹P NMR (200 MHz, CDCl₃): δ 149.7, 149.6; HRMS (ESI-Ion Trap) *m/z*: [M+H]⁺ calcd for C₄₀H₇₈N₂O₆P⁺, 713.5592; found 713.5578.

[Type here]




2-Cyanoethyl-*N,N*-diisopropylamine-(1-hexadecanoyl-2-(9*Z*-octadecanoyl)-*sn*-glycero)-3-

phosphoramidite (14): 1-Palmitoyl-2-oleoyl-*sn*-glycerol **6** (0.12 g, 0.20 mmol) was dissolved in dry CH₂Cl₂ (1.8 mL) and then bisdiisopropylamine cyanoethyl phosphoramidite (0.08 mL, 0.24 mmol) was added to the reaction solution followed by the addition of tetrazole (0.45 M in CH₃CN, 0.44 mL, 0.20 mmol). The reaction stirred at rt for 1 h before diluting with degassed CH₂Cl₂ (~10 mL) and worked up as described in the general protocol. The crude product was purified by flash column chromatography to afford a mixture of diastereomers **14** as a colourless oil (0.13 g, 82% yield): R_f = 0.51 (4:1 hexanes:EtOAc); ¹H NMR (800 MHz, CDCl₃): δ 5.37 – 5.30 (m, HC=CH, 2H), 5.19 (m, *sn*-2-CH, 1H), 4.34 (ddd, *J* = 30.8, 11.9, 3.8 Hz, *sn*-3-CH_a, 1H), 4.16 (ddd, *J* = 22.2, 11.9, 6.3 Hz, *sn*-3-CH_b, 1H), 3.85 (m, CH_aCH₂CN, 1H), 3.82 – 3.75 (m, CH_bCH₂CN, *sn*-1-CH_a, 2H), 3.72 – 3.65 (m, *sn*-1-CH_b, 1H), 3.62 – 3.54 (m, 2xCH, 2H), 2.63 (m, CH₂CN, 2H), 2.33 – 2.27 (m, 4H), 2.00 (dt, *J* = 12.6, 6.5 Hz, 4H), 1.65 – 1.58 (m, 4H), 1.35 – 1.21 (m, 46H), 1.19 – 1.14 (m, 12H), 0.88 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (200 MHz, CDCl₃): δ 173.6, 173.1, 130.2 (C=C), 129.9 (C=C), 117.7 (C≡N), 70.8 (app. t, *J* = 7.4, 7.4 Hz, *sn*-2-C), 62.5 (d, *J* = 4.0 Hz, *sn*-1-C), 61.9 (d, *J* = 16.2 Hz, *sn*-3-C), 61.7 (d, *J* = 16.2 Hz, *sn*-3-C), 58.6 (app. t, *J* = 17.9, 17.9 Hz, CH₂CH₂CN), 43.3 (d, *J* = 2.9 Hz, N-CH), 43.2 (d, *J* = 2.9 Hz, N-CH), 34.45, 34.27, 32.07, 32.05, 29.91, 29.87, 29.85, 29.82, 29.81, 29.79, 29.67, 29.64, 29.51, 29.47, 29.45, 29.37, 29.36, 29.29, 29.24, 27.37, 27.32, 25.06, 25.04, 24.75, 24.71, 22.83, 20.5 (d, *J* =

[Type here]


6.6 Hz, CH₂CN), 14.27, 1.16; ³¹P NMR (200 MHz, CDCl₃): δ 149.5, 149.4; HRMS (ESI-Ion Trap) *m/z*: [M+Na]⁺ calcd for C₄₆H₈₇N₂O₆NaP, 817.6199; found 817.6226.




2-Cyanoethyl-*N,N*-diisopropylamine-(1-hexadecanoyl-2-(9-cyclopropyl-nonadecanoyl)-*sn*-glycero)-3-phosphoramidite (15): Diacylglycerol **12** (0.14 g, 0.23 mmol) was dissolved with dry CH₂Cl₂ (1.00 mL). Bisdiisopropylamine cyanoethyl phosphoramidite (0.15 mL, 0.47 mmol) was added followed by the addition of tetrazole (0.45 M in CH₃CN, 1.03 mL, 0.47 mmol). After 1 h at room temperature, the reaction was quenched and worked up as described in the general protocol. The crude was purified by flash column chromatography to afford a mixture of diastereomers **15** (0.13 g, 82% yield) as a clear oil: [α]_D²⁵ +3.11 (*c* 0.009, CHCl₃); R_f = 0.60 (4:1 hexanes:EtOAc); ¹H NMR (600 MHz, CDCl₃): δ 5.10 – 5.09 (m, *sn*-2-CH, 1H), 4.26 (dd, *J* = 11.9, 3.8 Hz, *sn*-1-CH_a, 0.5H), 4.22 (dd, *J* = 11.9, 3.8 Hz, *sn*-1-CH_a, 0.5H), 4.08 (dd, *J* = 11.9, 6.2 Hz, *sn*-1-CH_b, 0.5H), 4.05 (dd, *J* = 11.9, 6.2 Hz, *sn*-1-CH_b, 0.5H), 3.77 – 3.66 (m, *sn*-3-CH_{2a}, PO-CH₂, 3H), 3.62 – 3.58 (m, *sn*-3-CH_{2b}, 1H), 3.51 – 3.47 (m, 2x N-CH, 2H), 2.55 – 2.52 (m, NC-CH₂, 2H), 2.23 – 2.19 (m, 2xCO-CH₂, 4H), 1.52 – 1.49 (m, 4H), 1.27 – 1.15 (m, 44H), 1.08 (t, *J* = 6.7 Hz, 2xCHCH₃, 12H), 0.78 (t, *J* = 6.3 Hz, 2xCH₃, 6H), 0.56 – 0.52 (m, cyclopropyl 2xCH, 2H), 0.46 (ddd, *J* = 9.4, 4.1, 4.1 Hz, cyclopropyl CH_{2a}, 1H), -0.44 (app. q, *J* = 9.4, 5.3, 4.3 Hz, cyclopropyl CH_{2b}, 1H); ¹³C NMR (150 MHz, CDCl₃): δ 173.5, 173.1 (d, *J* = 2.3 Hz, *sn*-2-CO), 117.7 (CN), 70.8 (d, *J* = 5.1 Hz, *sn*-2-CH), 70.7 (d, *J* = 5.1 Hz, *sn*-2-CH), 62.5 (d, *J* = 2.6 Hz, *sn*-1-CH₂), 61.9 (d, *J* = 16.4 Hz, *sn*-3-CH₂), 61.7 (d, *J* = 16.4 Hz, *sn*-3-CH₂), 58.7 (d, *J* =

[Type here]

12.4 Hz, PO-CH₂), 58.6 (d, *J* = 12.4 Hz, PO-CH₂), 43.4 (d, *J* = 1.9 Hz, N-CH), 43.3 (d, *J* = 1.9 Hz, N-CH), 34.5, 34.2, 32.1, 30.4, 30.3, 29.8, 29.8, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 28.9, 28.8, 25.1, 25.0, 24.8, 24.7, 22.8, 20.5 (d, *J* = 6.7 Hz, NC-CH₂), 15.9 (cyclopropyl CH), 15.8 (cyclopropyl CH), 14.3, 11.1 (cyclopropyl CH₂); ³¹P NMR (200 MHz, CDCl₃): δ 149.5, 149.4; HRMS (ESI-Ion Trap) *m/z*: [M+H]⁺ calcd for C₄₅H₈₆N₂O₆P⁺, 781.6218; found 781.6221.




[Type here]



Cholesteryl 2,3,4,6-tetra-*O*-trimethylsilyl- α -D-glucopyranoside (4)² : In a flame dried argon purged round bottom containing 4 Å molecular sieves (300 mg) was added TBAI (140 mg, 0.38 mmol, 4.5 eq.), cholesterol (32 mg, 0.083 mmol, 1.0 eq.), and anhydrous dichloromethane (2.5 mL). Hünig's base (90 μ L, 0.51 mmol, 6.0 eq.) was then added to the solution, which was stirred for 30 min. In a separate flame dried argon purged round bottom flask was placed per-*O*-trimethylsilylated glucose (140 mg, 0.25 mmol, 3.0 equiv). After azeotrope with anhydrous benzene (2 x 3 mL), per-*O*-TMS glucose was diluted with anhydrous dichloromethane (2.5 mL) and TMSI (40 μ L, 0.28 mmol, 3.3 eq.) was added and allowed to react for 10 min at rt. The in situ generated glucosyl iodide was then transferred via cannula into the acceptor flask and allowed to stir for 2 d at rt. The solvent was then filtered to remove the molecular sieves and the solvent was removed under reduced pressure. A 1:1 ratio of ethyl acetate and hexanes (20 mL) was then added to the round bottom flask and the solution was cooled in a dry ice/acetone bath causing the excess TBAI to precipitate. The solid was filtered and the solution was again concentrated to give an oil. The crude mixture was purified by gradient flash column chromatography (0 \rightarrow 8 % hexanes:EtOAc) to afford **4** as a clear syrup (78 % yield): $[\alpha]_{\text{D}}^{25} +27.4$ (c 0.002, CHCl_3); $R_f = 0.29$ (98:2 hexanes:EtOAc); $^1\text{H NMR}$ (600 MHz, C_6D_6): δ 5.41 (app. d, $J = 5.1$ Hz, H-6, 1H), 5.01 (d, $J = 3.4$ Hz, H-1', 1H), 4.20 (app. t, $J = 8.9$ Hz, 1H, H-3'), 3.96 (m, 1H, H-5'), 3.92 (dd, $J = 3.7, 11.6$ Hz, 1H, H-6'), 3.87 (app. t, $J = 8.9$ Hz, 1H, H-4'), 3.82 (dd, $J = 1.5, 11.6$ Hz, 1H, H-6''), 3.63 (dd, $J = 3.4, 9.1$ Hz, H-2', 1H), 3.61-3.57 (m, H-3, 1H), 2.57-2.47 (m, H-4, 2H), 2.00 (m, 1H), 1.94-1.89 (m, H-7, 2H), 1.84-1.81 (m, 1H), 1.71-1.69 (m, 1H), 1.61-

[Type here]


1.57 (m, H-2, 2H), 1.56-1.50 (m, 2H), 1.43-1.34 (m, 7H), 1.26-1.16 (m, 5H), 1.13-1.04 (m, 3H), 1.01-0.96 (m, 5H), 0.93 (dd, $J = 1.8, 6.5$ Hz, 7H), 0.88 (s, 3H), 0.65 (s, 3H), 0.33 (s, Si-(CH₃)₃, 9H), 0.31 (s, Si-(CH₃)₃, 9H), 0.19 (s, Si-(CH₃)₃, 9H), 0.13 (s, Si-(CH₃)₃, 9H); ¹³C NMR (150 MHz, C₆D₆): δ 141.2 (C-5), 121.9 (C-6), 98.2 (C-1'), 78.0 (C-3), 75.5 (C-3'), 74.3 (C-2'), 73.3 (C-5'), 72.5 (C-4'), 62.3 (C-6'), 57.0, 56.5, 50.6, 42.6, 40.9, 40.2 (C-4), 40.0, 37.5, 37.0, 36.7, 36.2, 32.4 (C-7), 32.2, 28.7, 28.5, 28.4, 24.6, 24.4, 23.1, 22.8, 21.4, 19.5, 19.1, 12.1, 1.70, 1.24, 0.64, 0.01; HRMS (ESI-Ion Trap) m/z : [M+Na]⁺ calcd for C₄₅H₈₈O₆NaSi₄, 859.5550; found 859.5578.



Cholesteryl 2,3,4-tri-O-trimethylsilyl- α -D-glucopyranoside (16): Glucoside **4** (0.14 g, 0.17 mmol) was azeotropically dried with dry benzene (3 x 3 mL) and placed under high vacuum for 6 h. To the clear foam was added NH₄OAc (0.03 g, 0.43 mmol) and the mixture was dissolved first with dry CH₂Cl₂ (1.00 mL) and then dry MeOH (1.00 mL) was added to the solution. The mixture was then stirred at rt for 16 h and then concentrated for gradient flash column chromatography (pre-treated with 4 % TEA in hexanes, 0 → 10 % EtOAc:hexanes) to afford **16** as a clear foam (0.12 g, 93% yield): $[\alpha]_D^{25} +20.0$ (c 0.002, CHCl₃); $R_f = 0.32$ (92:8 hexanes:EtOAc); ¹H NMR (600 MHz, C₆D₆): δ 5.40 (app. d, $J = 4.0$ Hz, H-6, 1H), 4.98 (d, $J = 3.5$ Hz, H-1', 1H), 4.20 (app. t, $J = 8.9$ Hz, H-3', 1H), 3.99 (m, H-5', 1H), 3.87 – 3.72 (m, H-4', H-6', H-6'', 3H), 3.59 (dd, $J = 9.2, 3.6$ Hz, H-2', 1H), 3.57 – 3.53 (m, H-3, 1H), 2.51 (d, $J = 7.6$

[Type here]

Hz, H-4, 2H), 2.03 (m, 1H), 1.98 – 1.89 (m, H-7, 2H), 1.89 – 1.81 (m, 1H), 1.74 (m, 1H), 1.67 – 1.59 (m, 2H), 1.55 (m, 3H), 1.48 – 1.17 (m, 14H), 1.16 – 1.05 (m, 3H), 1.02 (d, $J = 6.5$ Hz, 4H), 0.94 (dd, $J = 6.6, 1.5$ Hz, 8H), 0.90 – 0.86 (m, 3H), 0.67 (s, 3H), 0.33 (s, 9H), 0.31 (s, 9H), 0.19 (s, 9H); ^{13}C NMR (150 MHz, C_6D_6): δ 141.0 (C-5), 122.1 (C-6), 98.3 (C-1'), 78.3 (C-3), 75.1 (C-3'), 74.2 (C-2'), 73.0 (C-5'), 72.4 (C-4'), 61.9 (C-6'), 57.0, 56.6, 54.4, 50.6, 46.5, 42.6, 42.1, 40.8, 40.2, 40.0, 37.6, 37.1, 37.0, 36.7, 36.2, 32.4, 32.2, 30.2, 28.7, 28.5, 28.5, 24.6, 24.4, 23.1, 22.8, 21.4, 19.4, 19.1, 12.1, 1.61, 1.14, 0.63; HRMS (ESI-Ion Trap) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{42}\text{H}_{80}\text{O}_6\text{NaSi}_3$, 787.5160; found 787.5145.




Cholesteryl 6-O-(1,2-tetradecanoyl-*sn*-glycero-3-phosphocynoethyl)- α -D-glucopyranoside

(17): Glucoside **16** (0.04 g, 0.06 mmol) and phosphoramidite **13** (0.16 g, 0.23 mmol) were azeotropically dried with dry benzene (3 x 5 mL) and placed under high vacuum for 15 h. The mixture was then diluted in dry CH_2Cl_2 (0.50 mL) and tetrazole (0.45 M in CH_3CN , 0.82 mL) was added. After stirring at rt for 40 h, the reaction mixture was diluted with CH_2Cl_2 (2 mL) and O_2 gas was bubbled through the mixture for 30 min. DOWEX H^+ (0.20 g) was added to the reaction and left stirring under O_2 for an additional 4 h. The DOWEX H^+ was filtered and washed with CHCl_3 . The filtrate was then washed with sat. NaHCO_3 , dried over MgSO_4 , filtered, and concentrated for gradient flash column chromatography (0 \rightarrow 10% MeOH:EtOAc

[Type here]

and then flushed with 30% MeOH:EtOAc) to afford a mixture of diastereomers of **17** (0.02 g, 32% yield, 75% BRSM): $R_f = 0.58$ (9:1 EtOAc: MeOH); $^1\text{H NMR}$ (600 MHz, CDCl_3 :MeOD 5:1) δ 5.29 – 5.28 (m, H-6, 1H), 5.23 – 5.17 (m, *sn*-2-CH, 1H), 4.92 (d, $J = 3.6$ Hz, H-1', 1H), 4.31 – 4.09 (m, *sn*-1-CH₂, *sn*-3-CH₂, PO-CH₂, H-6', 8H), 3.78 – 3.74 (m, H-5', 1H), 3.60 (app. t, $J = 8.9, 8.9$ Hz, H-3', 1H), 3.42 – 3.38 (m, H-3, 1H), 3.36 (dd, $J = 8.9, 3.6$ Hz, H-2', 1H), 3.34 – 3.32 (m, H-4', 1H), 2.76 – 2.74 (m, NC-CH₂, 2H), 2.30 – 2.25 (m, 2xCO-CH₂, H-4, 6H), 1.97 – 1.90 (m, H-7, 2H), 1.87 – 1.74 (m, 3H), 1.57 – 1.53 (m, 5H), 1.49 – 1.37 (m, 6H), 1.27 – 1.17 (m, 45H), 1.12 – 0.98 (m, 7H), 0.95 (s, 3H), 0.93 – 0.89 (m, 2H), 0.86 – 0.79 (m, 15H), 0.62 (s, 3H); $^{13}\text{C NMR}$ (150 MHz, CDCl_3 :MeOD 5:1) δ 173.6, 173.5, 173.2, 173.1, 140.5 (C-5), 122.0 (C-6), 121.9 (C-6), 116.5 (CN), 116.4 (CN), 97.1 (C-1'), 97.0 (C-1'), 78.2 (C-3), 78.1 (C-3), 73.9 (C-3'), 73.8 (C-3'), 71.8 (C-2'), 70.3 (C-5'), 70.2 (C-5'), 69.3 (app. t, $J = 7.5, 7.5$ Hz, *sn*-2-CH, C-4'), 67.5 (d, $J = 5.4$ Hz, C-6'), 67.4 (d, $J = 5.4$ Hz, C-6'), 66.0 (app. t, $J = 5.0, 5.0$ Hz, *sn*-3-CH₂), 62.4 (d, $J = 5.7$ Hz, PO-CH₂), 62.3 (d, $J = 5.2$ Hz, PO-CH₂), 61.7 (*sn*-1-CH₂), 61.6 (*sn*-1-CH₂), 56.7, 56.1, 50.1, 42.2, 40.0, 39.7, 39.4, 36.9, 36.6, 36.1, 35.7, 34.1, 33.9, 31.8, 31.7, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 29.0, 28.1, 27.9, 27.7, 24.8, 24.2, 23.7, 22.6, 22.5, 22.4, 20.9, 19.4, 19.3, 19.2, 18.6, 13.9, 11.7; $^{31}\text{P NMR}$ (200 MHz, CDCl_3 :MeOD 5:1): δ -1.62; HRMS (ESI-Ion Trap) m/z : $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{67}\text{H}_{122}\text{N}_2\text{O}_{13}\text{P}^+$, 1193.8679; found 1193.8807.

[Type here]




18

Cholesteryl 6-O-(1-hexadecanoyl-2-(9Z-octadecanoyl)-sn-glycero-3-phosphocyclohexyl)- α -D-glucopyranoside (18): Glucoside **16** (0.03 g, 0.03 mmol) and phosphoramidite **14** (0.11 g, 0.14 mmol) were azeotropically dried with dry benzene (3 x 5 mL) and placed under high vacuum for 2 h. The mixture was then diluted in dry CH₂Cl₂ (0.5 mL) and tetrazole (0.45 M in CH₃CN, 0.47 mL) was added. After stirring at rt for 40 h, the reaction mixture was diluted with CH₂Cl₂ (2 mL) and O₂ gas was bubbled through the mixture for 30 min. DOWEX H⁺ (0.20 g) was added to the reaction and left stirring under O₂ for an additional 4 h. The DOWEX H⁺ was filtered and washed with CHCl₃. The filtrate was then washed with sat. NaHCO₃, dried over MgSO₄, filtered, and concentrated for gradient flash column chromatography (0 →10% MeOH:EtOAc and then flushed with 30% MeOH:EtOAc) to afford a mixture of diastereomers of **18** (0.02 g, 40% yield, 66% BRSM): R_f = 0.58 (9:1 EtOAc: MeOH); ¹H NMR (600 MHz, CDCl₃:MeOD 5:1) δ 5.40 – 5.29 (m, 3H, HC=CH, H-6), 5.26 (m, 1H, *sn*-2-CH), 5.03 (d, *J* = 3.7 Hz, 1H, H-1'), 4.45 (m, 1H, H-6'), 4.38 – 4.13 (m, 7H, *sn*-1-CH₂, *sn*-3-CH₂, CH₂CH₂CN, H-6''), 3.86 – 3.77 (m, 1H, H-5'), 3.73 (m, 1H, H-3'), 3.59 – 3.52 (m, 1H, H-4'), 3.52 (m, 2H, H-2', H-3), 2.78 (m, 2H, CH₂CN), 2.34 (m, 6H, 2xCO-CH₂, H-4), 2.01 (m, 6H, CH₂CH=CHCH₂, H-7), 1.88 (m, 4H), 1.61 (m, 6H), 1.54 – 1.40 (m, 6H), 1.38 – 1.19 (m, 45H), 1.18 – 1.04 (m, 8H), 1.04

[Type here]

– 0.95 (m, 6H), 0.88 (m, 17H), 0.68 (s, 3H); ^1H NMR (600 MHz, $\text{C}_5\text{D}_5\text{N}:\text{MeOD}$) δ 5.79 – 5.73 (m, 1H, *sn*-2-CH), 5.59 (bs, 1H, H-6), 5.57 – 5.50 (m, 3H, HC=CH, H-1'), 4.96 – 4.86 (m, 2H, H-6', H-6''), 4.81 – 4.70 (m, 2H, H-4', *sn*-1-CH_a), 4.61 (m, 6H, *sn*-1-CH_b, *sn*-3-CH₂, CH₂CH₂CN, H-3'), 4.15 (dd, $J = 3.7, 9.6$ Hz, 1H, H-2'), 4.13 – 4.08 (m, 1H, H-5'), 3.89 – 3.78 (m, 2H, H-3), 3.16 – 3.07 (ddd, $J = 6.2, 6.2, 18.7$ Hz, 2H, CH₂CN), 2.80 – 2.71 (m, 1H, H-4), 2.63 – 2.47 (m, 4H, 2xCO-CH₂), 2.17 (m, 4H, CH₂CH=CHCH₂), 2.06 (m, 2H, H-7), 1.95 – 1.81 (m, 3H), 1.74 (m, 4H), 1.71 – 1.62 (m, 3H), 1.58 (m, 2H), 1.50 – 1.40 (m, 8H), 1.40 – 1.25 (m, 34H), 1.24 – 1.17 (m, 4H), 1.17 – 1.09 (m, 3H), 1.07 – 0.99 (m, 6H), 0.98 – 0.87 (m, 11H), 0.74 (m, 3H); ^{13}C NMR (150 MHz, $\text{C}_5\text{D}_5\text{N}:\text{MeOD}$) δ 173.6, 173.4, 141.6 (C-5), 130.7 (HC=CH), 130.6 (HC=CH), 122.4 (C-6), 118.3 (C≡N), 99.46 (C-1'), 99.43 (C-1'), 80.3 (C-3), 78.7, 77.8 (CH₂CH₂CN), 75.9 (C-2'), 74.4 (C-3'), 72.8 (C-5'), 72.7 (C-5'), 72.1 (C-4'), 71.9 (d, $J = 6.2$ Hz, *sn*-2-CH), 69.3 (d, $J = 6.8$ Hz, C-6'), 66.8 (d, $J = 3.7$ Hz, *sn*-3-C), 63.4, 62.7 (*sn*-1-C), 57.2, 56.8, 56.7, 50.7, 42.9, 41.1, 40.4, 40.2, 37.8, 37.3, 36.9, 36.5, 34.8, 34.6, 32.7, 32.5, 32.5, 30.5, 30.4, 30.4, 30.4, 30.3, 30.2, 30.1, 30.1, 30.0, 30.0, 29.9, 29.8, 29.8, 28.9, 28.8, 28.8, 28.7, 28.0, 25.6, 24.9, 24.6, 23.4, 23.3, 23.1, 21.7, 20.3, 20.2, 19.9, 19.4, 14.7, 12.4; ^{31}P NMR (200 MHz, CDCl_3): δ -0.52, -0.56; HRMS (ESI-Ion Trap) m/z : $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{73}\text{H}_{132}\text{N}_2\text{O}_{13}\text{P}^+$, 1275.9462; found 1275.9510.

[Type here]




Cholesteryl 6-O-(1-tetradecanoyl-2-(9-cyclopropyl-nonadecanoyl)-sn-glycero-3-phosphocynoethyl)- α -D-glucopyranoside (19): Glucoside **16** (0.05 g, 0.06 mmol) and phosphoramidite **15** (19 g, 0.25 mmol) were azeotropically dried with dry benzene (3 x 5 mL) and placed under high vacuum for 16 h. The mixture was then diluted in dry CH₂Cl₂ (0.50 mL) and tetrazole (0.45 M in CH₃CN, 0.89 mL, 0.40 mmol) was added. After stirring at rt for 40 h, the reaction mixture was diluted with CH₂Cl₂ (2 mL) and O₂ gas was bubbled through the mixture for 30 min. DOWEX H⁺ (0.25 g) was added to the reaction and left stirring under O₂ for an additional 4 h. The DOWEX H⁺ was filtered and washed with CHCl₃. The filtrate was then washed with sat. NaHCO₃, dried over MgSO₄, filtered, and concentrated for gradient flash column chromatography (0 → 10% MeOH:EtOAc and then flushed with 30% MeOH:EtOAc) to afford a mixture of diastereomers of **19** (0.02 g, 24% yield, 56% BRSM): R_f = 0.58 (9:1 EtOAc: MeOH); ¹H NMR (800 MHz, CDCl₃:MeOD 1:1) δ 5.35 – 5.32 (m, H-6, 1H), 5.28 – 5.24 (m, *sn*-2-CH, 1H), 4.95 (d, *J* = 3.5 Hz, H-1', 1H), 4.38 – 4.34 (m, *sn*-1-CH_{2a}, 1H), 4.33 – 4.30 (m, H-6', 2H), 4.29 – 4.19 (m, PO-CH₂, *sn*-3-CH_{2a}, 3H), 4.18 – 4.14 (m, *sn*-1-CH_{2b}, *sn*-3-CH_{2b}, 2H), 3.84 – 3.76 (m, H-5', 1H), 3.78 – 3.62 (m, H-3', 1H), 3.49 – 3.41 (m, H-3, 1H), 3.38 (dd, *J* = 9.6, 3.6 Hz, H-2', 1H), 3.34 – 3.30 (m, H-4', 1H), 3.16 (TEA), 2.85 – 2.82 (m, NC-CH₂, 2H), 2.36 – 2.30 (m, 2xCO-CH₂, H-4, 5H), 2.01– 1.98 (m, H-7, 2H), 1.97 – 1.79 (m, 3H), 1.63 – 1.56 (m, 5H),

[Type here]

1.53 -1.40 (m, 5H), 1.39 – 1.18 (m, 55H), 1.18 – 1.02 (m, 8H), 1.00 (s, 3H), 0.93 – 0.81 (m, 15H), 0.67 (s, 3H), 0.65 – 0.61 (m, cyclopropyl 2xCH, 2H), 0.54 (ddd, $J = 8.2, 3.9, 4.2$ Hz, cyclopropyl CH_{2a}, 1H), -0.36 (app. q, $J = 8.2, 4.8, 4.8$ Hz, cyclopropyl CH_{2b}, 1H); ¹³C NMR (200 MHz, CDCl₃:MeOD 1:1) δ 174.3, 173.8, 141.3 (C-5), 141.2 (C-5), 122.5 (C-6), 122.4 (C-6), 117.4 (CN), 117.3 (CN), 97.9 (C-1'), 97.9 (C-1'), 78.9 (C-3), 78.8 (C-3), 74.4 (C-3'), 72.5 (C-2'), 71.1 (C-5'), 71.0 (C-5'), 70.4 (C-4'), 70.3 (C-4'), 70.1 (*sn*-2-CH), 70.0 (*sn*-2-CH), 68.5 (d, $J = 5.3$ Hz, C-6'), 68.3 (d, $J = 3.5$ Hz, C-6'), 66.8 (d, $J = 5.5$ Hz, *sn*-3-CH₂), 66.7 (d, $J = 5.0$ Hz, *sn*-3-CH₂), 63.2 (d, $J = 5.2$ Hz, PO-CH₂), 63.1 (d, $J = 4.7$ Hz, PO-CH₂), 62.4 (*sn*-1-CH₂), 62.3 (*sn*-1-CH₂), 57.4, 56.8, 50.8, 47.3, 42.9, 40.7, 40.4, 40.1, 37.6, 37.3, 36.7, 36.4, 34.7, 34.5, 34.5, 32.5, 30.7, 30.2, 30.2, 30.1, 30.0, 29.9, 29.9, 29.8, 29.7, 29.7, 29.6, 29.3, 29.2, 28.8, 28.5, 28.3, 25.4, 25.4, 24.8, 24.3, 23.2, 23.1, 22.8, 21.6, 19.9, 19.7, 19.1, 16.3, 16.2, 14.3, 12.2, 11.3, 9.1 (cyclopropyl CH₂); ³¹P NMR (200 MHz, CDCl₃:MeOD 1:1): δ -1.94; HRMS (ESI-Ion Trap) m/z : [M+NH₄]⁺ calcd for C₇₂H₁₃₀N₂O₁₃P⁺, 1261.9305; found 1261.9305.

General protocol for the deprotection of 17-19: Compound (17-19) was dissolved with dry CH₂Cl₂ (1.00 mL) and DBU (20 μ L). The reaction was stirred at rt for 3 min and then quenched with HOAc (20 μ L). Progress of the reaction was followed by TLC (R_f of α CPG 0.56-0.7 using 7:3:0.5 CHCl₃:MeOH:NH₄OH 0.1 M and the spot is below the spot for α CG) The solution was then concentrated and purified gradient flash column chromatography (5:4:1 CHCl₃:Acetone:IPA \rightarrow 5:4:1 CHCl₃:Acetone:MeOH \rightarrow 5:3:2 CHCl₃:Acetone:MeOH) to afford α CPG (3a-3c).

[Type here]




3a

Cholesteryl 6-O-(1,2-hexadecanoyl-*sn*-glycero-3-phosphate)- α -D-glucopyranoside (3a):

Glucoside **18** (6 mg, 0.1 mmol) was dissolved in dry CH₂Cl₂ (1.0 mL) and deprotected according to the general procedure above. After work-up and purification α CPG **3a** (5 mg, 88% yield) was attained as an amorphous white solid: $[\alpha]_D^{24} +24.0$ (*c* 0.001, CHCl₃:MeOH 1:1); *R_f* = 0.60 (7:3:0.5 CHCl₃:MeOH:NH₄OH 0.1 M); ¹H NMR (600 MHz, CDCl₃:MeOD:TEA 0.1M in CDCl₃ 4:1.5:0.5): δ 5.30 (app. br. s, H-6, 1H), 5.19 (app. br. s, *sn*-2-CH, 1H), 4.93 (app. br. s, H-1', 1H), 4.37 – 4.35 (m, *sn*-1-CH_{2a}, 1H), 4.21 – 4.10 (m, *sn*-1-CH_{2b}, H-6', 2H), 3.95 (app. br. s, *sn*-3-CH₂, 2H), 3.91 – 3.85 (m, H-6'', 1H), 3.69 – 3.58 (m, H-5', H-3', 2H), 3.57 – 3.49 (m, H-4', 1H), 3.46 – 3.36 (m, H-3, H-2', 2H), 2.68 (TEA), 2.29 – 2.25 (m, H-4, 2xCO-CH₂, 6H), 2.03 – 1.74 (m, H-7, 5H), 1.62 – 1.38 (m, 10H), 1.36 – 1.16 (m, 37H), 1.08 (TEA), 0.96 (s, 4H), 0.91 – 0.78 (m, 12H), 0.64 (s, 3H); ¹³C NMR (150 MHz, CDCl₃:MeOD:TEA 0.1M in CDCl₃ 4:1.5:0.5): δ 174.2, 173.8, 140.7 (C-5), 122.3 (C-6), 97.4 (C-1'), 78.2 (C-3), 73.4 (C-3'), 72.4 (C-2'), 71.6 (d, *J* = 3.2 Hz, C-5'), 70.7 (d, *J* = 8.3 Hz, *sn*-2-CH), 69.2 (C-4'), 64.4 (d, *J* = 5.6 Hz, C-6'), 63.9 (d, *J* = 4.6 Hz, *sn*-3-CH₂), 62.8 (*sn*-1-CH₂), 57.0, 56.4, 50.4, 46.1 (TEA), 42.6, 40.3, 40.0, 39.8, 37.3, 36.9, 36.4, 36.1, 34.5, 34.3, 32.2, 29.9, 29.9, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 28.5, 28.2, 27.9, 25.2, 25.1, 24.5, 24.1, 22.9, 22.7, 21.3, 19.5, 18.9, 14.2, 12.0 10.1 (TEA); ³¹P NMR (200 MHz,

[Type here]


CDCl₃:MeOD:TEA 0.1M in CDCl₃ 4:1.5:0.5): δ 1.41 ; HRMS (ESI-Ion Trap) m/z : [M-1]⁻ calcd for C₆₄H₁₁₄O₁₃P⁻, 1121.8003; found 1121.7961.



Cholesteryl 6-O-(1-hexadecanoyl-2-(9Z-octadecanoyl)-sn-glycero-3-phosphate)- α -D-glucopyranoside (3b): Compound **20** (0.02 g, 0.02 mmol) was diluted in CH₂Cl₂ (1.00 mL) and then DBU (0.02 mL, 0.13 mmol) was added to the solution. The reaction was stirred for 3 min before being quenched with HOAc (0.02 mL). The crude mixture was then concentrated for gradient flash column chromatography (9:1 EtOAc:MeOH \rightarrow 60:20:1 CHCl₃:MeOH:H₂O) to afford **3b** as a gel (17 mg, 91% yield): $[\alpha]_D^{25}$ +36.8 (c 0.001, CHCl₃:MeOH 4:1); R_f = 0.56 (7:3:0.5 CHCl₃:MeOH:NH₄OH 0.1 M); ¹H NMR (800 MHz, CDCl₃:DBU:CD₃COOD): δ 5.38 – 5.28 (m, HC=CH, H-6, 3H), 5.22 (m, *sn*-2-CH, 1H), 5.01 (d, J = 3.5 Hz, H-1', 1H), 4.42 (app. t, J = 11.7 Hz, H-6', 1H), 4.38 (dd, J = 2.3, 11.8 Hz, *sn*-1-CH_a, 1H), 4.17 (dd, J = 11.9, 6.5 Hz, *sn*-1-CH_b, 1H), 4.00 (m, *sn*-3-CH₂, 2H), 3.94 – 3.86 (m, H-6'', 1H), 3.80 (app. t, J = 9.4 Hz, H-3', 1H), 3.67 – 3.58 (m, H-4', H-5', 2H), 3.48 (m, DBU, H-2', H-3, 21H), 2.30 (m, 2xCO-CH₂, H-4, 6H), 2.05 – 1.93 (m, DBU, CH₂CH=CH-CH₂, H-7, 17H), 1.85 – 1.71 (m, DBU, 17H), 1.72 – 1.61 (m, 13H), 1.61 – 1.54 (m, 6H), 1.54 – 1.39 (m, 8H), 1.40 – 1.18 (m, 58H), 1.18 – 1.03 (m, 10H), 1.00 (m, 6H), 0.94 – 0.76 (m, 22H), 0.69 (s, 3H); ¹³C NMR (200 MHz,

[Type here]

CDCl₃:DBU:CD₃COOD): δ 173.6, 173.2, 140.6 (C-5), 130.2 (C=C), 129.9 (C=C), 122.2 (C-6), 97.2 (C-1'), 78.0 (C-3), 73.9 (C-3'), 72.7 (C-2'), 72.1 (d, $J = 2.6$ Hz, C-5'), 70.6 (d, $J = 4.3$ Hz, *sn*-2-CH), 68.9 (C-4'), 64.2 (d, $J = 6.8$ Hz, C-6'), 63.7 (d, $J = 4.3$ Hz, *sn*-3-CH₂), 62.8 (*sn*-1-CH₂), 56.9, 56.3, 50.2, 49.7, 45.1, 42.4, 40.2, 39.9, 39.7, 37.3, 37.1, 36.8, 36.3, 35.9, 35.3, 34.5, 34.3, 32.4, 32.1, 32.0, 30.1, 29.9, 29.8, 29.7, 29.5, 29.4, 28.6, 28.4, 28.2, 27.4, 27.3, 25.1, 24.5, 24.0, 23.6, 23.0, 22.9, 22.7, 21.2, 19.5, 18.9, 14.3, 12.0; ; ³¹P NMR (200 MHz, CDCl₃): δ 2.41 ; HRMS (ESI-Ion Trap) m/z : [M-1]⁻ calcd for C₇₀H₁₂₄O₁₃P⁻, 1203.8785; found 1203.8781.



3c

Cholesteryl 6-*O*-(1-tetradecanoyl-2-(9-cyclopropyl-nonadecanoyl)-*sn*-glycero-3-phosphate)- α -D-glucopyranoside (3c): Glucoside **20** (0.02 g, 0.1 mmol) was dissolved in dry CH₂Cl₂ (1.0 mL) and deprotected according to the general procedure above. After work-up and purification α CPG **3c** (14 mg, 92% yield) was attained as an amorphous chalk white solid: [α]_D²⁴ +16.3 (c 0.001, CHCl₃:MeOH 4:1); R_f = 0.61 (7:3:0.5 CHCl₃:MeOH:NH₄OH 0.1 M); ¹H NMR (800 MHz, CDCl₃:MeOD 1:1): δ 5.33 (app. br. s, H-6, 1H), 5.22 (app. br. s, *sn*-2-CH, 1H), 4.94 (app. br. s, H-1', 1H), 4.42 – 4.41 (m, *sn*-1-CH_{2a}, 1H), 4.20 – 4.14 (m, *sn*-1-CH_{2b}, H-6'a, 2H), 3.99 – 3.92 (m, *sn*-3-CH₂, H-6'b, 3H), 3.68 – 3.60 (m, H-5', H-3', 2H), 3.57 – 3.49 (m, H-4', 1H), 3.47

[Type here]

- 3.37 (m, H-3, H-2', 2H), 2.33 - 2.27 (m, 2xCO-CH₂, H-4, 6H), 2.01 - 1.99 (m, H-7, 1H), 1.96 - 1.94 (m, 2H), 1.86 - 1.82 (m, 3H), 1.58 - 1.57 (m, 6H), 1.51 - 1.41 (m, 7H), 1.36 - 1.18 (m, 56H), 1.17 - 1.03 (m, 11H), 1.01 - 0.94 (m, 6H), 0.92 - 0.83 (m, 22H), 0.67 (s, 3H), 0.65 - 0.61 (m, cyclopropyl 2x CH, 2H), 0.55 (ddd, $J = 9.4, 4.2, 3.9$ Hz, cyclopropyl CH_{2a}, 1H), -0.36 (app. q, $J = 9.4, 4.9, 4.9$ Hz, cyclopropyl CH_{2b}, 1H); ¹³C NMR (200 MHz, CDCl₃:MeOD 1:1): δ 174.5, 174.2, 141.2 (C-5), 122.5 (C-6), 97.9 (C-1'), 78.5 (C-3), 73.9 (C-3'), 72.8 (C-2'), 71.9 (d, $J = 5.3$ Hz, C-5'), 71.1 (d, $J = 6.4$ Hz, *sn*-2-CH), 69.9 (C-4'), 64.9 (d, $J = 6.4$ Hz, C-6'), 64.3 (d, $J = 4.3$ Hz, *sn*-3-CH₂), 63.2 (*sn*-1-CH₂), 57.4, 56.8, 50.8, 49.5, 49.4, 42.9, 40.7, 40.4, 40.1, 37.7, 37.3, 36.8, 36.4, 34.8, 34.6, 32.5, 30.8, 30.7, 30.3, 30.3, 30.2, 30.2, 30.2, 30.1, 30.1, 30.1, 30.0, 29.9, 29.9, 29.8, 29.7, 29.3, 28.8, 28.5, 28.2, 25.5, 25.4, 24.8, 24.4, 23.2, 23.1, 22.8, 21.6, 19.7, 19.1, 16.3 (cyclopropyl CH), 16.2 (cyclopropyl CH), 14.4, 12.2, 11.3 (cyclopropyl CH₂); ³¹P NMR (200 MHz, CDCl₃:MeOD 1:1): δ 0.83 ; HRMS (ESI-Ion Trap) m/z : [M-1]⁻ calcd for C₆₉H₁₂₂O₁₃P⁻, 1189.8629; found 1189.8588.

References

- (1) Ioannou, P. V.; Dodd, G. H.; Golding, B. T. *Synthesis-Stuttgart* **1979**, 939.
- (2) Davis, R. A. F., James C.; Gervay-Hague, Jacquelyn *Submitted* **2014**.